NCIC CLINICAL TRIALS GROUP
BRAIN DISEASE SITE COMMITTEE MEETING
AGENDA - OPEN SESSIONS
Venue: Carlyle
Date: Saturday, May 3rd 2014 Time: 9:00 a.m. – 12:00 p.m.
Chair: Dr. Warren Mason

9:00 am Welcome and Introductions

COMPLETED STUDIES

9:05 am IND. 204: A Phase II Study of the Phosphatidylinositol-3-OH Kinase (PI3K) Inhibitor PX-866 in Recurrent Glioblastoma
M. Pitz

9:10 am CE5 (EORTC 22033-26033): Primary Chemotherapy with Temozolomide vs Radiotherapy in Patients with Low-Grade Gliomas After Stratification for Genetic 1P Loss: A Phase III Study
W. Mason

CE.5S: The Sociobehavioural Effects of Primary Chemotherapy with Temozolomide vs Radiotherapy in Patients with Low-Grade Gliomas After Stratification for Genetic 1P Loss: A Phase III Study
A. Leis

TRIALS CLOSED TO ACCRUAL

9:15 am CE.6: A Randomized Phase III Study of Temozolomide a Short-Course Radiation versus Short-Course Radiation Alone in the Treatment of Newly Diagnosed Glioblastoma Multiforme in Elderly Patients
J. Perry

ACTIVELY ACCRUING TRIALS

9:20 am CEC.1 (EORTC 26053_22054): Phase III Trial of Concurrent and Adjuvant Temozolomide Chemotherapy in Non-1p/19Q Deleted Anaplastic Glioma. The CATNON Intergroup Trial
W. Mason

9:25 am CEC.3 (NCCTG N107C): A Phase III Trial of Post-Surgical Stereotactic Radiosurgery Compared with Whole Brain Radiotherapy (WBRT) for Resected Metastatic Brain Disease
D. Roberge

NEW TRIALS/CONCEPTS FOR DISCUSSION

9:30 am (Alliance 071102) Randomized Trial of ABT-888 or Placebo in Combination with Adjuvant Temozolomide in Newly Diagnosed GBM with MGMT Promoter Hypermethylation
P. Brown
PREVIOUSLY APPROVED/REVISED TRIALS

9:50 am  **CEC.2 (Alliance N0577)** Phase III Intergroup Study of Temozolomide Alone versus Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic Glioma. The CODEL Intergroup Trial  

W. Mason

10:00-10:15  **Coffee Break**

NEW TRIALS/CONCEPTS FOR DISCUSSION

10:15 am  **(Alliance 221208)** Randomized Phase II Study: Corticosteroids + Bevacizumab vs Corticosteroids + Placebo (BeSt) for Radionecrosis after Radiosurgery for Brain Metastases  

C. Chung

10:35 am  A Phase II/III Randomized, Double-Blind, Placebo-Controlled Clinical Trial Of Conventional Concurrent Chemoradiation and Adjuvant Temozolomide Plus BBI608 versus Conventional Concurrent Chemoradiation and Adjuvant Temozolomide In Patients With Newly Diagnosed Glioblastoma  

D. Kerstein

11:05 am  **(ECOG)** Phase III Non-Inferiority Trial Comparing Radiation with Concurrent Temozolomide With or Without Six Months of Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma  

L. Kleinberg

11:25 am  Glycemic Impact on Glioblastoma Outcomes (GIGO) Study  

C. Chung

MISCELLANEOUS

11:45 am  **Terry Fox Research Institute (TRFI) Grant: Therapeutic Targeting of GBM Project Status Report**  

D. Kaplan

11:55 am  **Report from IND Committee**  

M. Pitz

12:00 pm  **Closing Remarks**